Alveolar macrophage proteinase/antiproteinase expression in lung function and emphysema

European Respiratory Journal

Volumn 43, Issue 1, 2014, Pages 82-91

  Ishii, Takeo ^a,b   Abboud, Raja T ^c   Wallace, Alison M ^a,c   English, John C ^c   Coxson, Harvey O ^a,c   Finley, Richard J ^c   Shumansky, Karey ^a   Paré, Peter D ^a,c   Sandford, Andrew J ^a,c  

^a ST PAUL S HOSPITAL   (Canada)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CARBON MONOXIDE; CATHEPSIN L; CATHEPSIN S; CYSTATIN C; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MESSENGER RNA; PROTEINASE; PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; LUNG CAPACITY; LUNG DIFFUSION; LUNG EMPHYSEMA; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MMP12 GENE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

AGED; CATHEPSIN L; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION PROFILING; HUMANS; LUNG; MACROPHAGES, ALVEOLAR; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY DIFFUSING CAPACITY; PULMONARY EMPHYSEMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; VITAL CAPACITY;

EID: 84891910656     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00174612     Document Type: Review

References (58)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
2. Antó JM, Vermeire P, Vestbo J, et al. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-994.
3. McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med 2001; 164: 1419-1424.
4. Hogg JC, Senior RM. Chronic obstructive pulmonary disease - part 2: Pathology and biochemistry of emphysema. Thorax 2002; 57: 830-834.
5. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
6. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: S29-S32.
7. Mocchegiani E, Giacconi R, Costarelli L. Metalloproteases/anti- metalloproteases imbalance in chronic obstructive pulmonary disease: Genetic factors and treatment implications. Curr Opin Pulm Med 2011; 17: Suppl. 1, S11-S19.
8. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997; 59: 63-88.
9. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: Suppl. 34, 50s-59s.
10. Wilson R. Bacteria, antibiotics and COPD. Eur Respir J 2001; 17: 995-1007.
11. Wallace AM, Sandford AJ, English JC, et al. Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema. COPD 2008; 5: 13-23.
12. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med 1995; 152: 2185-2198.
13. Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002; 11: 569-576.
14. Minematsu N, Nakamura H, Tateno H, et al. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001; 289: 116-119.
15. Zhou M, Huang SG, Wan HY, et al. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 2004; 117: 1481-1484.
16. Shimajiri S, Arima N, Tanimoto A, et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinasee gene. FEBS Lett 1999; 455: 70-74.
17. Hirano K, Sakamoto T, Uchida Y, et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: 748-752.
18. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769.
19. Hintze J. NCSS and PASS. 2004. Number Cruncher Statistical Systems. Kaysville, UT. www.ncss.com. Date last accessed: June 5, 2013.
20. Arakaki PA, Marques MR, Santos MC. MMP-1 polymorphism and its relationship to pathological processes. J Biosci 2009; 34: 313-320.
21. Mbewe-Campbell N, Wei Z, Zhang K, et al. Genes and environment: Novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure. J Hypertens 2012; 30: 1961-1969.
22. Mitaki S, Nagai A, Sheikh AM, et al. Contribution of cystatin C gene polymorphisms to cerebral white matter lesions. Cerebrovasc Dis 2011; 32: 489-496.
23. Eriksson P, Deguchi H, Samnega°rd A, et al. Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 2004; 24: 551-557.
24. Benussi L, Ghidoni R, Steinhoff T, et al. Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol Dis 2003; 13: 15-21.
25. LoewM, Hoffmann MM, KoenigW, et al. Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arterioscler Thromb Vasc Biol 2005; 25: 1470-1474.
26. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-2608.
27. Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997; 277: 2002-2004.
28. Churg A, Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003; 167: 1083-1089.
29. Okada Y, Gonoji Y, Naka K, et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992; 267: 21712-21719.
30. Gronski TJ Jr, Martin RL, Kobayashi DK, et al. Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem 1997; 272: 12189-12194.
31. Molet S, Belleguic C, Lena H, et al. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res 2005; 54: 31-36.
32. Demedts IK, Morel-Montero A, Lebecque S, et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 2006; 61: 196-201.
33. Russell REK, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26: 602-609.
34. Bracke K, Cataldo D, Maes T, et al. Matrix metalloproteinase-12 and cathepsin D expression in pulmonary macrophages and dendritic cells of cigarette smoke-exposed mice. Int Arch Allergy Immunol 2005; 138: 169-179.
35. Reilly JJ Jr, Chen P, Sailor LZ, et al. Cigarette smoking induces an elastolytic cysteine proteinase in macrophages distinct from cathepsin L. Am J Physiol 1991; 261: L41-L48.
36. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001; 2: 10-19.
37. D'Armiento J, Dalal SS, Okada Y, et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992; 71: 955-961.
38. Imai K, Dalal SS, Chen ES, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001; 163: 786-791.
39. Segura-Valdez L, Pardo A, Gaxiola M, et al. Upregulation of gelatinases A and B, collagenasess and 2, and increased parenchymal cell death in COPD. Chest 2000; 117: 684-694.
40. Gosselink JV, Hayashi S, Elliott WM, et al. Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 1329-1335.
41. Xu B, Chen H, Xu W, et al. Molecular mechanisms of MMP9 overexpression and its role in emphysema pathogenesis of Smad3-deficient mice. Am J Physiol Lung Cell Mol Physiol 2012; 303: L89-L96.
42. Foronjy R, Nkyimbeng T, Wallace A, et al. Transgenic expression of matrix metalloproteinase-9 causes adult-onset emphysema in mice associated with the loss of alveolar elastin. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1149-L1157.
43. Churg A, Wang RD, Tai H, et al. Tumor necrosis factor-A drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004; 170: 492-498.
44. Honey K, Benlagha K, Beers C, et al. Thymocyte expression of cathepsin L is essential for NKT cell development. Nat Immunol 2002; 3: 1069-1074.
45. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9: 503-510.
46. Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (inmunoferó n). Am J Respir Crit Care Med 2001; 163: 1578-1583.
47. Nakagawa T, Roth W, Wong P, et al. Cathepsin L: Critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998; 280: 450-453.
48. Zhang T, Maekawa Y, Sakai T, et al. Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice. Int Immunol 2001; 13: 975-982.
49. Sevenich L, Hagemann S, Stoeckle C, et al. Expression of human cathepsin L or human cathepsin V in mouse thymus mediates positive selection of T helper cells in cathepsin L knock-out mice. Biochimie 2010; 92: 1674-1680.
50. Schurigt U, Eilenstein R, Gajda M, et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment. Inflamm Res 2012; 61: 1021-1029.
51. Funkelstein L, Beinfeld M, Minokadeh A, et al. Unique biological function of cathepsin L in secretory vesicles for biosynthesis of neuropeptides. Neuropeptides 2010; 44: 457-466.
52. Vatrella A, Montagnani S, Calabrese C, et al. Neuropeptide expression in the airways of COPD patients and smokers with normal lung function. J Biol Regul Homeost Agents 2010; 24: 425-432.
53. Iranmanesh A, Rochester DF, Liu J, et al. Impaired adrenergic- and corticotropic-axis outflow during exercise in chronic obstructive pulmonary disease. Metabolism 2011; 60: 1521-1529.
54. Cohly H, Stephens J, Markhov A, et al. Cell culture conditions affect LPS inducibility of the inflammatory mediators in J774A.1 murine macrophages. Immunol Invest 2001; 30: 1-15.
55. Tian J, Ishibashi K, Honda S, et al. The expression of native and cultured human retinal pigment epithelial cells grown in different culture conditions. Br J Ophthalmol 2005; 89: 1510-1517.
56. Neumann E, Riepl B, Knedla A, et al. Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2010; 12: R83.
57. Reynier F, de Vos AF, Hoogerwerf JJ, et al. Gene expression profiles in alveolar macrophages induced by lipopolysaccharide in humans. Mol Med 2012; 18: 1303-1311.
58. Hu C, Wang J, Xu Y, et al. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: A meta-analysis. Gene 2013; 517: 65-71.